Skip to main content
Clinical Trials/NCT03196596
NCT03196596
Completed
N/A

The Value of Patient-specific Computer Simulation in the Planning of TAVI With the Self-expanding Evolut R Valve

Erasmus Medical Center5 sites in 5 countries80 target enrollmentMay 23, 2017

Overview

Phase
N/A
Intervention
Not specified
Conditions
Aortic Valve Stenosis
Sponsor
Erasmus Medical Center
Enrollment
80
Locations
5
Primary Endpoint
Decision 2- Valve size decision after knowledge of the computer simulation results
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

Transcatheter aortic valve implantation is increasingly used to treat patients with severe aortic stenosis who are at increased risk for surgical aortic valve replacement and is projected to be the preferred treatment modality. As patient selection and operator experience have improved, it is hypothesised that device-host interactions will play a more dominant role in outcome. This, in combination with the increasing number of valve types and sizes, confronts the physician with the dilemma to choose the valve that best fits the individual patient. This necessitates the availability of pre-procedural computer simulation that is based upon the integration of the patient-specific anatomy, the physical and (bio)mechanical properties of the valve and recipient anatomy derived from in-vitro experiments. Patient-specific computer simulation may improve outcome of TAVI by proposing the valve size that best fits the individual patient.

The aim of this study is to assess the added value of patient-specific computer simulation in valve size selection.

Registry
clinicaltrials.gov
Start Date
May 23, 2017
End Date
January 31, 2019
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

P de Jaegere

MD, PhD, Professor

Erasmus Medical Center

Eligibility Criteria

Inclusion Criteria

  • Native severe aortic valve stenosis
  • Planned for TAVI with the Evolut R Valve

Exclusion Criteria

  • Bicuspid aortic valve
  • Extensive subannular calcifications
  • Non-transfemoral access
  • Poor CT quality
  • Lack of written informed consent

Outcomes

Primary Outcomes

Decision 2- Valve size decision after knowledge of the computer simulation results

Time Frame: an average of 1 day before TAVI, before TAVI but after computer simulation

Valve size decision after availability of the results of computer simulation

Decision 1- Valve size decision based on pre TAVI MSCT

Time Frame: an average of 2 days before TAVI, before TAVI and computer simulation

Valve size decision based on pre TAVI Multislice Computed Tomography (MSCT), which is performed in all patients referred for TAVI in accordance to clinical routine, during the heart team meeting

Secondary Outcomes

  • Depth of implantation target 2(an average of 1 day before TAVI, before TAVI but after computer simulation)
  • Correlation between predicted contact pressure and observed new conduction abnormality(an average of 4 days after TAVI, at hospital discharge)
  • Incidence of the aforementioned outcome measures in a prospective group in whom no computer simulation will be perfomed(an average of 4 days after TAVI, at hospital discharge)
  • MACCE(an average of 4 days after TAVI, at hospital discharge)
  • Decision 3- Change of initial valve size decision during TAVI(an average of 5 minutes after TAVI, directly after TAVI)
  • Decision 3- Change of initial depth of implantation strategy during TAVI(an average of 5 minutes after TAVI, directly after TAVI)
  • Depth of implantation target(an average of 2 days before TAVI, before TAVI and computer simulation)
  • Aortic regurgitation(an average of 4 days after TAVI, at hospital discharge)

Study Sites (5)

Loading locations...

Similar Trials